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PET imaging of putative microglial activation in
individuals at ultra-high risk for psychosis, recently
diagnosed and chronically ill with schizophrenia
MA Di Biase1,2, A Zalesky1,2,3, G O'keefe4,5, L Laskaris1,2, BT Baune6, CS Weickert1,7,8,9, J Olver2,4,5, PD McGorry10,11, GP Amminger10,
B Nelson10, AM Scott4,5, I Hickie12, R Banati13, F Turkheimer14, M Yaqub15, IP Everall2,16,17,18,19, C Pantelis1,2,16,17,18,19,20 and
V Cropley1,2,20
We examined putative microglial activation as a function of illness course in schizophrenia. Microglial activity was quantiﬁed
using [11C](R)-(1-[2-chrorophynyl]-N-methyl-N-[1-methylpropyl]-3 isoquinoline carboxamide (11C-(R)-PK11195) positron emission
tomography (PET) in: (i) 10 individuals at ultra-high risk (UHR) of psychosis; (ii) 18 patients recently diagnosed with schizophrenia;
(iii) 15 patients chronically ill with schizophrenia; and, (iv) 27 age-matched healthy controls. Regional-binding potential (BPND) was
calculated using the simpliﬁed reference-tissue model with four alternative reference inputs. The UHR, recent-onset and chronic
patient groups were compared to age-matched healthy control groups to examine between-group BPND differences in 6 regions:
dorsal frontal, orbital frontal, anterior cingulate, medial temporal, thalamus and insula. Correlation analysis tested for BPND
associations with gray matter volume, peripheral cytokines and clinical variables. The null hypothesis of equality in BPND between
patients (UHR, recent-onset and chronic) and respective healthy control groups (younger and older) was not rejected for any group
comparison or region. Across all subjects, BPND was positively correlated to age in the thalamus (r= 0.43, P= 0.008, false discovery
rate). No correlations with regional gray matter, peripheral cytokine levels or clinical symptoms were detected. We therefore found
no evidence of microglial activation in groups of individuals at high risk, recently diagnosed or chronically ill with schizophrenia.
While the possibility of 11C-(R)-PK11195-binding differences in certain patient subgroups remains, the patient cohorts in our study,
who also displayed normal peripheral cytokine proﬁles, do not substantiate the assumption of microglial activation in schizophrenia
as a regular and deﬁning feature, as measured by 11C-(R)-PK11195 BPND.
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INTRODUCTION
Multiple lines of evidence implicate altered immune function in
schizophrenia, including epidemiological, biomolecular, genetic
studies and clinical trials of adjunctive anti-inﬂammatory
treatments.1–3 Recent reviews1,4 summarize a still inconclusive
body of work suggesting that in some cases of psychosis,
activated microglia, the brain’s normally innate immune effector
cells,5 may be found in the brain parenchyma using immunohis-
tochemical staining techniques. In response to brain insult,
microglial cells become activated by changing shape and function
to upregulate molecules involved in cytokine release, phagocy-
tosis and antigen presentation.6
Seminal experimental studies have shown that activation of
microglia in the wake of a neuronal lesion (without blood–brain
barrier damage) induces a preferential de novo expression of the
18 kD translocator protein (TSPO) in the mitochondria of activated
microglia.7,8 Using 11C-(R)-PK11195 positron emission tomography
(PET), estimates of TSPO expression levels of above those seen in
control subjects and indicative of the presence of activated
microglia have been reported for brain diseases with known
inﬂammatory, vascular or neurodegenerative tissue pathology.9
A number of TSPO-binding studies have examined microglial
activation in schizophrenia,10–21 producing mixed results. The
initial studies in recent-onset patients10,11 revealed increased 11C-
(R)-PK11195 ligand binding to TSPO, providing impetus for further
research. However, subsequent TSPO investigations have gener-
ally failed to replicate these ﬁndings, including recent studies
using 11C-(R)-PK1119515,16,21 and second-generation tracers,12,13,17
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as well as studies investigating antipsychotic-naive patient
cohorts.15,20 Despite accumulating evidence for unchanged TSPO
levels in schizophrenia, both increased,10,11,19 and, more recently,
decreased18,20 TSPO levels have also been reported. Thus, the
presence and nature of microglial abnormalities in schizophrenia
remains unclear.
Differences in the pharmacokinetic and dynamic properties of
TSPO radioligands represent a potential reason for these
conﬂicting results. Apart from discrepant radioligands across
studies, patient heterogeneity, medication, methodological con-
siderations and, importantly, stage of illness may also contribute.
Notably, increased TSPO binding has been reported in patient
populations with shorter illness duration11 and individuals at high
clinical risk of psychosis,19 providing preliminary evidence of
TSPO-binding declining with illness chronicity. Alternatively, two
recent investigations19,20 using the same ligand, [11C]PBR-28, have
produced conﬂicting results, with TSPO increased in individuals at
risk of psychosis,19 yet decreased in ﬁrst-episode psychosis.20
Notably, both patient cohorts were antipsychotic-naive, suggest-
ing that antipsychotic medication effects did not explain the
ﬁndings. Although differences in methodology may have
accounted for the discrepant results,20,22 it remains possible that
microglial expression ﬂuctuates throughout the course of illness,
with increased expression occurring before the manifestation of
overt symptoms. Nevertheless, to date, no single study has
examined TSPO binding in pre-psychotic, or across stages in the
course of schizophrenia, and, with the exception of Bloomﬁeld
et al.,19 prodromal or at-risk cohorts have not been further
investigated.
Therefore, we tested whether the presence of activated
microglia varies dynamically as a function of illness stage, by
mapping TSPO expression in individuals at ultra-high risk (UHR) of
psychosis, recently diagnosed and with chronic schizophrenia.
Regions previously associated with gray matter loss in early stages
of schizophrenia were tested for altered microglial activation in
these three groups of individuals, as indexed by 11C-(R)-PK11195-
binding potential, and compared to age-matched comparison
subjects. We also tested whether 11C-(R)-PK11195-binding was
associated with gray matter volume, peripheral cytokine levels
and/or clinical symptoms. We hypothesized that increased 11C-(R)-
PK11195, indicating TSPO expression by activated microglia,
might occur in frontal and temporal brain regions in individuals
at risk and in early stages of schizophrenia, compared to healthy
controls and patients with prolonged illness.
MATERIALS AND METHODS
Participants
The study was approved by the Melbourne Health and Austin Health ethics
committees and all participants provided written informed consent. Three
recent-onset patients were excluded from the study due to poor PET
image quality, a history of seizures or an abnormality in the magnetic
resonance imaging (MRI) T1-weighted scan. A total of 70 participants were
included in this study: 10 individuals at UHR for psychosis, 18 recent-onset
schizophrenia patients (illness durationo2 years), 15 chronic schizophre-
nia patients (illness duration45 years) and 27 healthy controls matched on
age, sex and parental education. Healthy controls were divided into
mutually exclusive younger (n= 15; age range= 18–25) and older (n=12;
age range= 31–42) groups to yield healthy comparison groups that were
matched in mean age to the patient groups. The older comparison group
was matched in mean age to chronic patients, whereas the younger group
was matched to both UHR individuals and recent-onset patients. Sample
characteristics are shown in Table 1.
Individuals meeting standardized ‘UHR’ criteria were approached and
interviewed to conﬁrm UHR status according to the Comprehensive
Assessment of At Risk Mental State,23 a structured interview designed to
assess sub-threshold psychosis symptoms. Brieﬂy, UHR patients met
criteria for one or more of the following categories, accompanied by a
decline in general functioning:
1. First-degree relative with a history of psychosis or the individual has a
schizotypal personality disorder;
2. Sub-threshold intensity/frequency of positive symptoms;
3. Brief limited intermittent psychotic symptoms with spontaneous
remission within 1 week.
Eligible recent-onset and chronic patients were diagnosed with a
schizophrenia-spectrum disorder according to the Diagnostic and Statis-
tical Manual of Mental Disorders, Fourth Edition.24 Diagnoses were
conﬁrmed using the Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID).24
Exclusion criteria for all participants included a history of head injury or
seizures, diagnosis of a neurological disorder, impaired thyroid functioning,
diabetes, pregnancy, contraindication to MRI scanning, generalized
inﬂammatory condition and treatment with immunosuppressive, corti-
coid/glucocorticoid, steroidal or non-steroidal anti-inﬂammatory medica-
tion within 2 weeks of scanning, due to potential interaction with 11C-(R)-
PK11195. All participants were asked to refrain from alcohol consumption
and tobacco use for 12 h prior to scanning. Additional exclusion criteria for
healthy controls were a history of mental illness (personally or in a ﬁrst
degree relative) or alcohol or drug dependence. Healthy controls were
interviewed by two trained investigators using the SCID to conﬁrm
participants had no history of diagnosable psychopathology.
Clinical measures
The following scales were administered within 1 week of the PET scan: the
SCID24 to conﬁrm diagnoses and assess exclusion criteria; the Expanded
Brief Psychiatric Rating Scale (BPRS)25 to provide a rating for general
psychopathology and positive symptoms, the Scale for the Assessment of
Negative Symptoms (SANS)26 to measure negative symptoms and the
Social and Occupational Functioning Assessment Scale (SOFAS)27 to index
social functioning.
Positron emission tomography acquisition
To assess regional microglial activation, PET scans utilizing the ligand 11C-
(R)-PK11195 were obtained on a Philips Gemini TF64 scanner at the
Department of Molecular Imaging and Therapy, Austin Hospital,
Melbourne, VIC, Australia. To minimize head movement, a thermoplastic
facemask was ﬁxed to the head of each participant prior to scanning. A low
dose CT scan was acquired to allow correction for tissue attenuation. PET
acquisition commenced with the injection of 11C-(R)-PK11195, which was
delivered as a bolus into the antecubital vein of each participant. Emission
data were acquired in listmode over 60 min and reconstructed post-
acquisition into 22 temporal frames (6 × 30 s, 7 × 60 s, 4 × 150 s, 2 × 300 s
and 3× 600 s) using List mode Time-of-Flight 3D Line of Response RAMLA
(Listmode TF-MLEM algorithm). Images were reconstructed with the
following parameters: image voxel size = 2 × 2× 2 mm, FOV= 256× 256×
180 mm and slice thickness = 2.0 mm.
Magnetic resonance imaging acquisition
MRI scans were acquired within 2 weeks of PET scanning on a 3-T Siemens
Trio at the Murdoch Childrens Research Institute, Royal Children’s Hospital,
Parkville, VIC, Australia. Scanning parameters were as follows: 3D SPGR
spoiled gradient T1 weighted, echo time= 3 ms, repetition time= 14 ms,
256 contiguous slices covering whole brain, 1 × 1× 1 mm voxels.
Image pre-processing
PET and T1 anatomical scans were processed using FMRIB's Software
Library (FSL).28 For each subject, dynamic PET volumes were reoriented to
standard Montreal Neurological Institute (MNI152) images and realigned to
the middle volume. T1-weighted volumes were skull-stripped and
manually checked to optimize extraction. Skull-stripped T1-weighted
volumes were ﬁrst registered to native PET space, using an averaged
PET volume (frames 1–8) as the registration target (FLIRT).29 Next, T1
volumes were registered to MNI152 standard space, following a two-step
procedure: ﬁrst, the afﬁne transformation was computed to match the T1
volume to the template (FLIRT);29 and second, nonlinear normalization
applied the deformation ﬁeld that warps the original T1 volume to the
template, setting the previous afﬁne transformation as the starting
estimate (FNIRT).30
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Regional binding potential
Six bilateral regions of interest (ROI) were selected based on prior research
reporting marked gray matter loss in the early stages of schizophrenia:31,32
dorsal frontal (superior and middle frontal cortex), orbital frontal, anterior
cingulate, medial temporal (hippocampus and parahippocampus), thala-
mus and insula. Regions were delineated using the automated anatomical
labeling atlas (AAL)33 projected onto individual PET space using the linear
afﬁne from T1 to PET and the inverse of the nonlinear warp from T1 to
MNI space.
Parametric maps of binding potential (BPND) were computed using the
basis-function implementation of the simpliﬁed reference-tissue model.34
For each individual, BPND was averaged over all voxels comprising each ROI
to yield a regionally averaged BPND estimate for each of the six ROIs. Four
alternative reference regions were investigated to deﬁne a reference time-
activity curve for the simpliﬁed reference-tissue model: (i) cerebellar gray
matter;15 (ii) a data-driven supervised clustering approach;35,36 (iii) gray
matter voxels with the lowest (10%) standard uptake values; and (iv) white
matter.37 Results pertaining to the cerebellar reference are presented here,
with other results relegated to Supplementary Material. Support for the
cerebellar reference is three-fold: (i) extracting reference data from plasma
is not ideal for use with 11C-(R)-PK11195, due to the highly variable kinetic
behavior of this tracer in plasma;38 (ii) previous post-mortem examination
detected lower [3H]PK11195-binding densities in cerebellar gray matter
relative to our ROIs;15,39 and (iii) there were no signiﬁcant differences in
cerebellar standard uptake values between patient and control groups
(f=2.5, P40.05; Supplementary Figure S1).
Measurement of gray matter volume
Gray matter volume maps were calculated for each participant using voxel-
based morphometry, as implemented using the computational anatomy
toolbox (CAT12) in statistical parametric mapping (SPM12) software (http://
www.ﬁl.ion.ucl.ac.uk/spm/software/spm12/) running in Matlab R2014b. In
brief, T1 images were normalized to a template space and segmented into
gray matter, white matter and cerebrospinal ﬂuid. Native-space gray matter
segments were then spatially aligned to a high-dimensional Diffeomorphic
Anatomical Registration Through Exponentiated Lie Algebra template and
normalized to MNI space. Gray matter voxels were multiplied by the linear
and nonlinear components of this deformation to provide a measure of the
absolute amount of GM tissue corrected for individual brain sizes. All images
passed the voxel-based morphometry quality check based on the ‘display one
slice’ and ‘check sample homogeneity of covariance’ modules. Images were
smoothed with an 8mm full-width-half-maximum Gaussian kernel. Mean gray
matter volume was extracted from the resulting modulated, normalized and
smoothed T1 volumes for the 6 cortical ROIs, using the AAL parcellation.
Measurement of peripheral cytokines
All subjects were fasting and blood samples were obtained between 0800
and 1100 hours within 1 week of the PET scan. Peripheral blood was
collected from participants in serum separating tubes (SSTII), which were
then stored at − 80 °C, pending analysis.
Three cytokines (interleukin 1 beta [IL-1β], tumor necrosis factor alpha
[TNF-α] and interleukin 6 [IL-6]) from the Human High-sensitivity T cell
Table 1. Sample characteristics
Young HC Older HC UHR Recent-onset Chronic
n= 15 n=12 n=10 n=18 n=15
Sex (male/female) 13/2 9/3 6/4 16/2 10/5
Smoking status (yes/no)a 6/9 2/10 3/7 12/6 8/7
M s.d. M s.d. M s.d. M s.d. M s.d.
Age 21.7 2.1 36.3 4.2 20.7 2.2 20.6 5.5 35.2 6.6
BMI 24.3 4.1 25.5 5.4 22 2.4 27.6 5.4 27.6 5.5
Injected activity 335.4 16.8 350.6 18.1 330.9 19 342.4 23.2 333.8 26.9
Speciﬁc activity 39.5 16.6 47.7 34.3 56.3 17.8 40.0 12.3 52.4 43.3
DOI (years) — — — — — — 1.5 1.0 13.6 8.8
Age of symptom onset — — — — — — 19.8 2.4 17.8 2.6
Symptoms
General pathology (BPRS total)b — — — — — — 38.3 10 48.4 12.4
Positive symptoms (BPRS subscore)b — — — — — — 12.6 4.6 19.5 7.8
Negative symptoms (SANS)b — — — — 30.3 12.7 23 13.5 35.5 19.9
General functioning (SOFAS)b, c 83.7 7.3 78.3 10.7 57.2 9.6 56.6 11.2 42.5 14.6
Medication
Antipsychotic dose (CPZ-EQ) — — — — — — 1444.1 2438.6 1582.4 1853.5
n % n %
Any antipsychotics — — — — — — 14 78 15 100
Typical treatment — — — — — — 2 11 9 60
Atypical treatment — — — — — — 12 67 3 20
Combined typical and atypical — — — — — — 0 0 3 20
No antipsychotic treatment — — — — — — 4 22 0 0
Any mood medication — — — — — — 4 22 6 40
No mood medication — — — — — — 14 78 9 60
Abbreviations: ACC, anterior cingulate cortex; BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; CPZ-EQ, chlorpromazine-equivalent dose (mg);
DOI, duration of illness; HC, healthy control; M, mean; n, number; SANS, Scale for the Assessment of Negative Symptoms; SOFAS, Social and Occupational
Functioning Assessment Scale; UHR, ultra-high-risk. aSigniﬁcant difference between chronic patients and older healthy controls (Po0.05). bSigniﬁcant increase
in chronic patients compared to recent-onset patients (Po0.05). cSigniﬁcant increase in chronic patients compared to UHR patients (Po0.05).
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assay (HST-CMAG28SPMX13, Merck Millipore, Billerica, MA, USA) were
quantiﬁed in duplicate using the Luminex Magpix assay in a subset of
participants (data not available for three participants), cytokine data were
not obtained in two older controls and one recent-onset patient). Inter-
assay co-efﬁcients were below 15% for all analytes assayed (CVo15%) and
intra-assay co-efﬁcients of variation (CV) were below 5% (CVo5%). The
average minimum detectable value across all plates was 0.23 pg ml− 1 for
1 l-1beta, 0.05 pg ml− 1 for IL-6 and 0.12 pg ml− 1 for TNF-α. Serum samples
were thawed at 4 °C and centrifuged at 1400 g for 5 min in order to
remove any aggregate protein. The supernatant was then transferred to a
new tube and diluted 1:2 in assay buffer supplied in the kit. A 7-point
standard curve was generated using the standards supplied in the assay,
which were reconstituted and serially diluted according to manufacturer’s
instructions. The data was generated using a 5-parameter logistic standard
curve ﬁt corrected for sample dilutions in the Millipore Analyst Software
(Merck Millipore).
Statistical analyses
Between-group differences. Regional BPND was normally distributed within
each group, as conﬁrmed by Shapiro–Wilk’s test (40.05) and homogeneity
of variances was checked by Levene’s test. Two-sample t-tests were used
to independently test the null hypothesis of equality in group means
between: (i) UHR individuals and the younger control group; (ii) recent-
onset patients and the younger control group; and (iii) chronic patients
and the older control group. These three null hypotheses were
independently tested for age, body mass index, amount of injected
activity, speciﬁc activity of the ligand and regional 11C-(R)-PK11195 BPND
for each of the six ROIs. The false discovery rate (FDR)40 was used to
provide error control across the six ROIs. Sex and smoking status were
compared between groups using Fisher’s exact test (two-tailed).
Peripheral cytokines and gray matter. Partial correlation analysis was used
to test for an association across all individuals (patients and controls)
between: (i) regional BPND (six regions) and gray matter volume (six
regions); as well as, (ii) BPND (six regions) and three peripheral serum
cytokines (IL1-β, TNF-α and IL-6). The FDR was used to provide error control
across the six correlations tested in the former correlation analysis, and the
18 correlations tested in the latter (6 regions × 3 cytokines). These
correlations controlled for age, as an association was detected between
age and thalamic BPND.
Medication and clinical symptoms. Among the pooled schizophrenia
groups (recent-onset and chronic patients), a partial correlation was used
to examine the relationship between regional BPND and chlorpromazine-
equivalent antipsychotic dose, while controlling for age. FDR correction
was applied across the six regional tests. Correlations of regional BPND with
positive (BPRS-positive subscale) and negative (SANS total) symptom
severity were examined separately in UHR, recent-onset and chronic
patients, with the FDR correction performed across the 12 tests in each
cohort (6 regions × 2 symptom scales). All reported P-values associated
with regional analyses were FDR corrected unless otherwise speciﬁed and
FDRo0.05 was considered statistically signiﬁcant. A trend was deﬁned as
FDRo0.1.
RESULTS
Demographics, clinical and biological parameters
There were no signiﬁcant differences in age, sex, body mass index,
injected or speciﬁc radioactivity or levels of cytokine markers
(Supplementary Figure S2) between patients and their respective
healthy control groups (FDRo0.05). There was a greater
proportion of smokers in the chronic patient group (53%),
compared to the age-matched control group (17%; χ2(1,
n= 27) = 3.84, P= 0.0499). Compared to age-matched controls,
UHR patients displayed signiﬁcantly increased gray matter volume
compared to healthy controls in the orbital frontal cortex
(P= 0.008; Supplementary Figure S3). In addition, recent-onset
patients displayed signiﬁcantly decreased gray matter volume in
the insular cortex relative to age-matched controls (P= 0.008;
Supplementary Figure S3). Gray matter volume did not signiﬁ-
cantly differ between chronic patients and older healthy controls
in any region examined (FDRo0.05).
Compared to recent-onset patients, chronic patients exhibited
signiﬁcantly greater general psychopathology (BPRS total) scores
(t(31) = 2.5, Po0.05), positive symptom (BPRS subscale) scores (t
(31) = 3.1, Po0.01), negative symptom (SANS total) scores
(t(31) = 2.1, Po0.05), as well as signiﬁcantly decreased general
functioning (SOFAS) scores (t(31) = 3.1, Po0.01). Furthermore,
chronic patients displayed signiﬁcantly decreased general func-
tioning (SOFAS scores) compared to UHR patients (t(23) = 2.8,
Po0.05). Therefore, potential associations between regional BPND
and positive and negative symptom scores were examined
separately in UHR, recent-onset and chronic patients.
Between-group comparisons of regional 11C-(R)-PK11195 BPND
No signiﬁcant differences in 11C-(R)-PK11195 BPND were found
between patients (UHR, recent-onset and chronic) and their
respective healthy control groups (younger and older; Table 2 and
Figure 1). Inclusion of smoking status and sex as nuisance
covariates did not change these results. In secondary analyses
examining the effects of medication, unmedicated patients (n= 4)
displayed lower BPND compared to antipsychotic-treated patients
(n= 29) and healthy controls (n= 27), after controlling for age
(Supplementary Figure S4). In supplementary analyses, no
signiﬁcant differences were also found using whole-brain, voxel-
wise analysis and BPND estimates derived using three alternative
reference regions (Supplementary Figure S5). With voxel-wise
analysis, each gray matter voxel was independently tested for a
between-group difference and cluster-based inference was used
to provide error control over the family of all voxels.41 This data-
driven supplementary analysis avoided the need for anatomically
deﬁned ROIs.
Table 2. Comparison of 11C-(R)-PK11195 BPND across the ﬁve study groups




UHR vs young HC Recent-onset vs
young HC
Chronic vs older HC
M s.d. M s.d. M s.d. M s.d. M s.d. t P d t P d t P d
Dorsal frontal 0.90 0.04 0.9 0.02 0.9 0.05 0.89 0.04 0.91 0.04 0.38 0.71 0.08 0.28 0.78 0.05 − 1.34 0.19 − 0.26
Orbital frontal 0.93 0.05 0.91 0.04 0.92 0.06 0.93 0.05 0.95 0.05 1.05 0.30 0.21 0.63 0.53 0.11 − 1.16 0.26 − 0.22
Medial temporal 0.80 0.04 0.80 0.03 0.80 0.04 0.8 0.04 0.82 0.02 − 0.23 0.82 − 0.05 0.24 0.81 0.04 − 1.32 0.20 − 0.25
Thalamus 0.93 0.06 0.92 0.05 0.91 0.04 0.98 0.04 0.96 0.06 0.19 0.85 0.04 1.01 0.32 0.18 0.88 0.39 0.17
Insular cortex 0.89 0.04 0.88 0.03 0.86 0.05 0.89 0.03 0.89 0.03 0.74 0.47 0.15 1.91 0.06 0.33 0.48 0.64 0.09
ACC 0.86 0.03 0.84 0.04 0.84 0.04 0.88 0.05 0.87 0.05 1.73 0.10 0.35 1.82 0.08 0.32 0.50 0.62 0.10
Abbreviations: ACC, anterior cingulate cortex; BPND, binding potential; d, effect size (Cohen’s d) HC, healthy control; M, mean; P, uncorrected P-value;
SCZ, schizophrenia; s.d., standard deviation; t, t statistic; UHR, ultra-high-risk. Equal variances not assumed.
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Correlations with regional 11C-(R)-PK11195 BPND
There was no relationship between chlorpromazine-equivalent
antipsychotic dose and BPND in any ROI (FDR o0.05). In contrast,
there was a positive correlation between age and BPND in the
thalamus of all groups combined (r= 0.43, P= 0.008, FDR; Figure 2).
Therefore, cytokine and clinical correlations with BPND were
examined with partial correlations, controlling for age. No
relationships were found with peripheral pro-inﬂammatory serum
cytokine levels, regional gray matter volumes or symptom severity
scores (positive and negative symptoms) in UHR, recent-onset or
chronic patients.
DISCUSSION
In the largest TSPO PET study in schizophrenia to date, we found
no evidence for differential 11C-(R)-PK11195-binding in individuals
at risk for psychosis, or patients recently diagnosed and
chronically ill with schizophrenia. In addition, 11C-(R)-PK11195
binding was not related to peripheral cytokines, gray matter
volume or clinical severity. Our study is consistent with an
increasing number of studies reporting no difference in TSPO
expression at various stages of schizophrenia.12,13,15,16,17,21 How-
ever, we report this ﬁnding across three distinct stages of illness in
the same study, with all individuals scanned and analyzed at the
same site.
In agreement with prior studies, thalamic BPND was positively
correlated to age across all subjects.8,16,19 This correlation was
observed in patients and controls separately (data not shown),
suggesting that TSPO expression may be more sensitive to normal
age-related increases than illness-related processes. Increased
thalamic TSPO expression may be sensitive to age by virtue of the
dense reciprocal thalamic connections with cortical and sub-
cortical brain areas allowing a signiﬁcant cumulative effect of
TSPO expression, while subtle more spatially distributed increases
may remain below detection levels in manifest areas of tissue
destruction or neurodegeneration.
Contrary to our hypothesis, we found no evidence of altered
11C-(R)-PK11195 BPND in either our UHR or recent-onset cohorts
relative to age-matched controls, suggesting that differences in
illness stage do not likely account for the discrepant ﬁndings of
recent studies using the same tracer.19,20 While statistically
signiﬁcant differences were not evident, 11C-(R)-PK11195 BPND
tended to be reduced in both UHR and recent-onset patients in the
insula and ACC, with an effect size of d= 0.35 and 0.32,
respectively; a notable preliminary observation given ﬁndings of
decreased TSPO expression in a recent study of unmedicated ﬁrst-
episode psychosis patients.20 Interestingly, in agreement with this
study, we found signiﬁcantly reduced TSPO in antipsychotic-naive
patients, suggesting that absence of TSPO elevation in our study is
not due to antipsychotic medication. These ﬁndings challenge the
assumption of increased TSPO expression in prodromal and early
stages of psychosis, and suggest that a downregulation of TSPO
may be involved in the pathophysiology of the illness, possibly
normalizing with antipsychotic treatment.
The possibility remains however that increased microglial
activation occurs in discrete subpopulations of patients42 deﬁned
by illness duration, symptom exacerbation,43 inﬂammation or gray
matter loss,44 which were not captured at the time of scanning or
by the current sample population. For example, although 11C-(R)-
PK11195 BPND did not differ across all three stages of illness and
was not related to duration of illness (data not shown), increased
(or decreased) TSPO expression could occur during speciﬁc time-
windows, such as during very early (that is, o2 months) illness.
Our recent-onset patients were scanned, on average, within the
ﬁrst 1.5 years of their illness, while microglial activation might
have been present only at the time of their ﬁrst psychotic episode.
Likewise, although we found no relationship between symptom
severity and TSPO expression, consistent with ﬁve previous
studies,10,11,14,16,20 our patient cohorts were relatively symptoma-
tically stable, limiting our ability to assess the contribution of
symptom exacerbation on TSPO availability.
Alternative to clinical factors, TSPO upregulation may be
associated with a patient subgroup deﬁned by high inﬂammation,
a notion supported by post-mortem studies in chronic
schizophrenia.42,45–48 Of note however, we found no BPND
differences between high and low inﬂammatory groups of
recent-onset patients, based on a median split of averaged and
scaled cytokine levels (data not shown). Nevertheless, a subgroup
possibility remains as our patient groups did not display elevated
pro-inﬂammatory cytokines relative to controls across the markers
examined in serum (IL1-β, TNF-α and IL-6) and hence, may not
represent ‘high inﬂammatory’ cohorts. Therefore, differences in
patient immune proﬁles, including peripheral cytokine levels, may
explain discrepancies between our study and previous ﬁndings of
increased TSPO expression. However, previous work by Coughlin
et al.17 found no association between [11C]DPA-713 distribution
Figure 1. Comparison of 11C-(R)-PK11195 BPND in individuals at ultra-
high risk, recently diagnosed and chronically ill with schizophrenia,
compared to age-matched comparison subjects. BPND did not differ
between patients and controls. Bars denote the mean value of BPND.
Controls are shown in blue and patients in red. Sagittal slices show
AAL regions investigated. ACC, anterior cingulate cortex; AAL,
automated anatomical labeling; BPND, binding potential; HC, healthy
controls; SCZ, schizophrenia; UHR, ultra-high risk.
Figure 2. Correlation between 11C-(R)-PK11195 BPND and age. BPND
was positively correlated to age in the thalamus. BPND, binding
potential.
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volume and plasma IL-6 levels in recent-onset patients with
signiﬁcantly increased IL-6 levels, suggesting that increased
peripheral inﬂammation may occur without increases in TSPO. In
line with this proposition, we did not detect a relationship
between peripheral cytokine markers and TSPO expression.
Further work is required to understand the relationship between
peripheral and central markers of inﬂammation, including TSPO.
Given the well-established ﬁndings of gray matter loss in
schizophrenia32,49 and the proposed link between gray matter loss
and microglial activation during acute illness,1 patients displaying
signiﬁcant gray matter loss may represent an alternative
subpopulation of patients with increased TSPO expression.
Notably, we did not detect signiﬁcantly reduced gray matter in
chronic patients relative to controls, despite a trend of decreased
volume across all regions examined, with an average effect size of
d= 0.3 (Supplementary Figure S3). Therefore, the absence of
between-group BPND differences may be due to our patient
populations, which did not display increased inﬂammation or gray
matter loss. Alternatively, our sample size may have been
insufﬁcient to identify such biological shifts, including a changed
TSPO signal. Nevertheless, it should be recognized that the sample
size of our patient cohorts were similar to, or greater than,
previous studies and, together, our patient sample represents the
largest PET TSPO study in schizophrenia to date.
It is lastly noteworthy that reduced TSPO levels in an infection-
mediated mouse model was recently associated with increased
cytokine expression,18 which challenges the assumption that low-
grade neuroinﬂammation (such as that possibly occurring in
schizophrenia), is reﬂected by an increase in TSPO. This suggests
that TSPO may not be the optimal target for imaging microglial
activation and neuroinﬂammation in schizophrenia. This might
partly be due to other TSPO mechanisms related to astrocytes,
TSPO density,50 glucose metabolism,51 glial mitochondria52 or
transcriptional events53 that contribute to the PET TSPO signal,
potentially underlying the mixed results and heterogeneity
observed across and within studies.18,20 In addition, microglial
activation is a highly diverse and dynamic process, involving
classically pro-inﬂammatory (M1) and neuroprotective (M2)
phenotypes, which may change in disease-speciﬁc contexts.54
Due to the heterogeneity of microglial function,54 it remains
possible that neuroinﬂammatory processes are present in schizo-
phrenia but are unable to be captured with current PET
techniques using radioligands for the TSPO. As the TSPO signal
does not solely represent microglial activation or neuroinﬂamma-
tion, in vivo PET studies would beneﬁt from the development of
markers speciﬁc to microglia phenotype and activation in order to
determine their role in the pathophysiology of schizophrenia.
Several aspects of our experimental design require considera-
tion. First, the ligand used in this study, 11C-(R)-PK11195, has
shown lower afﬁnity for the TSPO relative to second-generation
ligands.22 Therefore, it could be argued that the lower signal-to-
noise of 11C-(R)-PK11195 in comparison to second-generation
ligands might have precluded the detection of subtle alterations
in TSPO. In turn, our results are contingent on 11C-(R)-PK11195,
and different conclusions might be reached with other tracers,
including those yielding higher-binding afﬁnity, such as [18F]-
FEPPA and [11C]PBR28 [ref. 55–57] and lower non-speciﬁc binding,
such as [11C]-DPA-713.58 On the other hand, it is unlikely that our
ﬁndings are ligand speciﬁc, as increased TSPO has been detected
in prior investigations using 11C-(R)-PK11195,10,11 and studies
using second-generation ligands have reported negative
ﬁndings.12–14,16,17 Second, it might be argued that our use
of a reference-tissue method resulted in inaccurate estimates of
11C-(R)-PK11195 BPND. We used a pseudo-reference region;
speciﬁcally, cerebellar gray matter, to derive the input. Although
this approach has been criticized on the basis that TSPO is
ubiquitous throughout the brain and within venous sinuses
around the cerebellum,36 cerebellar gray matter represents a
reasonable compromise.15 Importantly, we found no signiﬁcant
difference in cerebellar BPND between patients and controls. Our
ﬁndings were also veriﬁed using simpliﬁed reference-tissue model
estimates applied with three additional reference inputs
(Supplementary Material), indicating robustness to the choice of
reference input. Moreover, supplementary analyses were per-
formed at the level of individual voxels to test for differential BPND
expression across the entire gray matter volume, without
reference to any prior regional hypotheses. These whole-brain,
data-driven analyses conﬁrmed our main ﬁndings, in that the null
hypothesis of equality in BPND between patient and control
groups was not rejected for any gray matter voxels.
In summary, we found no evidence of 11C-(R)-PK11195-binding
differences in groups of individuals at high risk, recently
diagnosed and chronically ill with schizophrenia. We conclude
that altered microglial activation, indexed by 11C-(R)-PK11195, is
stable across stages in the course of illness and does not
signiﬁcantly differ compared to healthy comparison subjects.
Therefore, illness duration is unlikely to be a confounding factor in
previous PET studies. It is possible however, that inﬂammatory
signals vary in patient subpopulations characterized by peripheral
inﬂammation, gray matter loss or symptom exacerbation.
Furthermore, our ﬁndings do not discount the possibility of
new-generation TSPO tracers and alternative imaging methodol-
ogies yielding signiﬁcant between-group differences in microglial
activation. Therefore, assessment of TSPO combined with
complimentary MRI measures of neuroinﬂammation59 and other
biomakers in larger samples is warranted.
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